See more : Shalag Industries Ltd (SALG.TA) Income Statement Analysis – Financial Results
Complete financial analysis of AcuCort AB (ACUC.ST) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of AcuCort AB, a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
- Aligos Therapeutics, Inc. (ALGS) Income Statement Analysis – Financial Results
- Vas Infrastructure Limited (VASINFRA.BO) Income Statement Analysis – Financial Results
- Shanghai Sanmao Enterprise (Group) Co., Ltd. (600689.SS) Income Statement Analysis – Financial Results
- Elnet Technologies Limited (ELNET.BO) Income Statement Analysis – Financial Results
- Biochar Now, Inc. (GPRC) Income Statement Analysis – Financial Results
AcuCort AB (ACUC.ST)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://www.acucort.com
About AcuCort AB
AcuCort AB (publ) develops and commercializes glucocorticoid dexamethasone films for the treatment of acute allergic conditions. It offers Zeqmelit, a medicine used for the treatment of severe and acute allergic reactions, croup in children, and chemotherapy-induced nausea and vomiting, as well as for the treatment of COVID-19 patients who need supplemental oxygen treatment. AcuCort AB (publ) was incorporated in 2006 and is based in Lund, Sweden.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cost of Revenue | -6.59M | -5.02M | -3.46M | -1.53M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 6.59M | 5.02M | 3.46M | 1.53M | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research & Development | -6.59M | -5.02M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 0.00 | 0.00 | 11.92M | 6.91M | 9.77M | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 0.00 | 0.00 | -628.50K | 837.59K | -1.40M | 0.00 | 0.00 | 0.00 |
| SG&A | 13.25M | 14.83M | 11.30M | 7.75M | 8.37M | 6.22M | 4.67M | 1.92M |
| Other Expenses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 19.84M | 14.83M | 11.30M | 7.75M | 8.37M | 6.22M | 4.67M | 1.92M |
| Cost & Expenses | 13.25M | 14.83M | 11.30M | 7.75M | 8.37M | 6.22M | 4.67M | 1.92M |
| Interest Income | 286.00K | 52.00K | 0.00 | 0.00 | 0.00 | 2.32K | 7.83K | 0.00 |
| Interest Expense | 728.00K | 16.00K | 26.00K | 16.83K | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | -442.00K | 52.00K | 450.00 | -1.00 | -1.00 | 0.00 | 0.00 | 0.00 |
| EBITDA | -13.69M | -14.77M | -11.32M | -7.77M | -8.37M | -6.22M | -4.67M | -1.92M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | -13.25M | -14.83M | -11.30M | -7.75M | -8.37M | -6.22M | -4.67M | -1.92M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income/Expenses | -442.00K | 36.00K | -25.94K | -16.83K | 921.00 | 1.60K | 7.59K | -26.18K |
| Income Before Tax | -13.69M | -14.79M | -11.32M | -7.77M | -8.37M | -6.22M | -4.66M | -1.95M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 0.00 | 0.00 | 0.00 | 1.00 | 0.00 | 0.00 | 0.00 |
| Net Income | -13.69M | -14.79M | -11.32M | -7.77M | -8.37M | -6.22M | -4.66M | -1.95M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | -0.16 | -0.38 | -0.29 | -0.30 | -0.32 | -0.43 | -0.42 | -0.18 |
| EPS Diluted | -0.16 | -0.38 | -0.29 | -0.30 | -0.32 | -0.43 | -0.42 | -0.18 |
| Weighted Avg Shares Out | 83.83M | 39.27M | 39.27M | 25.98M | 25.80M | 14.37M | 11.09M | 11.09M |
| Weighted Avg Shares Out (Dil) | 83.83M | 39.27M | 39.27M | 25.98M | 25.80M | 14.37M | 11.09M | 11.09M |
Source: https://incomestatements.info
Category: Stock Reports